ClinicalTrialsFinder
RecruitingNCT06349642

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

Sponsor

Mayo Clinic

Enrollment

324 participants

Start Date

Apr 24, 2024

Study Type

OBSERVATIONAL

Conditions

Metastatic Cervical CarcinomaMetastatic Endometrial CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmStage III Renal Cell Cancer AJCC v8Stage IV Cervical Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Metastatic Colorectal CarcinomaMetastatic Liver CarcinomaEarly Stage Triple-Negative Breast CarcinomaRecurrent Malignant Solid NeoplasmRecurrent Endometrial CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMetastatic Esophageal CarcinomaMetastatic Malignant Skin NeoplasmResectable Lung Non-Small Cell CarcinomaEarly Stage Lung Non-Small Cell CarcinomaResectable Malignant Solid NeoplasmResectable Triple-Negative Breast CarcinomaRecurrent Cervical CarcinomaRecurrent Colorectal CarcinomaRecurrent Esophageal CarcinomaRecurrent Liver CarcinomaRecurrent Lung Non-Small Cell CarcinomaRecurrent Malignant Skin Neoplasm

Summary

This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study uses a new technology platform — a "live tumor" test done on a biopsy sample — to predict in the lab whether a patient's cancer will respond to immunotherapy drugs (called immune checkpoint inhibitors) before the patient actually receives them. **You may be eligible if...** - You have been diagnosed with stage IV or metastatic cancer of the lung, skin, esophagus, cervix, uterus, colon (if mismatch repair deficient), liver, or any solid tumor with specific genetic features (high mutation burden or microsatellite instability) - Your doctor is planning to treat you with an immune checkpoint inhibitor - A biopsy is either already planned or can be obtained as part of your care **You may NOT be eligible if...** - A biopsy cannot be safely obtained - You have a cancer type not covered by the study's criteria - You are unable or unwilling to provide consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDUREBiospecimen Collection

Undergo optional research blood sample.

PROCEDURETissue Collection

Tissue specimen collection will be completed with your scheduled standard of care biopsy if possible. If standard of care biopsy is already completed or the research biopsy wasn\'t collected at the time as your standard of care biopsy, then the research biopsy will be scheduled for a different day for research purposes only.

Locations(3)

Mayo Clinic in Arizona

Phoenix, Arizona, United States

Mayo Clinic in Florida

Jacksonville, Florida, United States

Mayo Clinic in Rochester

Rochester, Minnesota, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06349642

Related Trials

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

NCT05554328296 locations

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377479 locations

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

NCT03191149344 locations

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

NCT03866382579 locations

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

NCT0595046414 locations